

## Special Issue

# The Molecular Basis of the Immune Response in Pulmonary Fibrosis

### Message from the Guest Editors

Different molecular mechanisms have been associated with the development and progression of pulmonary fibrosis. Environmental chronic exposures induce repetitive microinjuries that cause an aberrant activation of the epithelial cells. There is an abnormal repair, mediated by the proliferation of fibroblasts, its activation into myofibroblasts, and the production of large amounts of extracellular matrix components. In addition, as an age-associated disease, there is an accumulation of senescent cells with a very active cytokine and extracellular matrix production. In this complex scenario, the lung immune response is a double-edged sword. While excess inflammation can result in further tissue damage and promote the fibrotic process, defects of immune surveillance and immune resolution allow for the accumulation of fibrosis and senescent cells. This Special Issue of *Biomedicines* aims to focus on recent advances identifying molecular mechanisms affecting the immune response in the fibrotic lung.

---

### Guest Editors

Dr. Tamara Cruz

Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS),  
08036 Barcelona, Spain

Dr. Fernanda Hernandez

Department of Respiratory Medicine, Respiratory Institute, Hospital  
Clinic Barcelona, 08036 Barcelona, Spain

---

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/226642](https://mdpi.com/si/226642)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).